Warnex Inc.

Warnex Inc.

August 12, 2005 07:00 ET

Warnex launches two novel tests for Campylobacter and 24-hour Listeria

LAVAL, QC, Aug. 12 - Warnex Inc. (TSX:WNX) announced today it is
launching two new tests for use with the Warnex™ Rapid Pathogen Detection
System. The first test detects Campylobacter jejuni, C. coli and C. lari in
poultry rinses, and the second is a one-step 24-hour test for Listeria species
in environmental samples. The distribution of these tests will begin in
September.

"As Campylobacter continues to emerge as a serious pathogen threatening
the safety of food, particularly poultry, and water, more companies are
beginning to screen for it as part of their regular quality assurance
practices," said Mark Busgang, President and CEO of Warnex. "Adding new tests
to our portfolio is an important aspect of our growth strategy as it allows us
to both leverage our existing installed base to drive additional reagent
revenue as well as attract new customers with a more comprehensive food safety
solution."

Warnex's Campylobacter test detects three species of this pathogen, which
account for 99% of reported Campylobacter illness cases. Contrary to
traditional testing methods for Campylobacter that require 5 to 7 days, this
test determines the presence of this pathogen within 48 hours. Warnex is
currently completing the development of a quantitative test that will
determine the amount of Campylobacter present in a sample. The Company intends
to start commercializing this test during the first quarter of 2006, making it
the first quantitative PCR test on the food testing market.

Warnex's new 24-hour Listeria spp. test for environmental samples has
three innovations: 1) it is a test for environmental swabs, 2) it has a single
enrichment step, thus simplifying the procedure, and 3) it provides results
within 24 hours instead of 48 hours. A significant proportion of pathogen
testing is used to monitor the environmental conditions of a food processing
plant, by collecting swab samples from processing equipment, as well as from
the walls, ceilings and floors of the plant. For example, in the dairy
industry, 75% of pathogens tests are performed on environmental samples.

According to the Centers for Disease Control and Prevention (CDC),
Campylobacter is one of the most common bacterial causes of diarrheal illness
in the United States, with an estimated 2.4 million cases every year. In
addition to diarrhea, Campylobacter infections cause cramping, abdominal pain,
and fever, and may occasionally spread to the bloodstream and cause a serious
life-threatening infection for persons with weakened immune systems.

According to USDA Food Safety and Inspection Service, the number one
cause of food recalls is Listeria. The CDC estimates 2,500 cases and 500
deaths occur in the United States annually due to Listeria infections.
Listeria infections affect primarily pregnant women, newborns, and persons
with weakened immune systems. Symptoms include headache, fever, and nausea,
but the infection may also result in miscarriage, stillbirth, blood infection,
meningitis, and even death, if untreated.

About Warnex

Warnex (www.warnex.ca) is a publicly traded (TSX: WNX) Canadian
biotechnology company devoted to protecting public health by providing
advanced diagnostic and quality control products and services to the
pharmaceutical, agri-food, and healthcare sectors. Warnex's genomics-based
technology offers a versatile detection platform that produces accurate
results rapidly, using Real-Time PCR technology combined with unique genetic
markers and software. Applications range from pathogen detection in foods and
GMO testing to farm-to-fork traceability using Molecular Bar Codes. Our
development pipeline includes applications in the detection of viruses,
toxins, yeasts, and fungi, as well as meat speciation and bioterrorism.
Warnex's profitable and growing analytical, bioanalytical, and clinical
service groups offer a variety of quality control services, method development
and validation, contract R&D, bioavailability and bioequivalence studies for
clinical trials, and medical laboratory testing.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and
are subject to numerous risks and uncertainties, known and unknown. For
information identifying known risks and uncertainties, such as market
conditions, currency, technological, financial, competitive and other
important factors that could cause actual results to differ materially from
those anticipated in the forward-looking statements, please refer to Warnex's
Annual Report under the heading Risks and Uncertainties in the Management's
Discussion and Analysis section. Consequently, actual results may differ
materially from the anticipated results expressed in these forward-looking
statements. Warnex disclaims any intention or obligation to update any
forward-looking statements, whether as a result of new information or
otherwise.

Contact Information